Genomics in Cancer Care Market is Going to be Worth $72.61 Billion by 2032

This is according to a recent Prophecy Market Insights report that covered a long list of different use cases and applications of genomics in the cancer care market. Cancer is a potentially fatal disease that is caused by an alteration to our genomic makeup. Currently, genomics is widely used in cancer treatment and diagnosis, but potential future uses include gene editing to alter our DNA directly.

There are a number of different genomics and biotech companies that are currently researching the cancer care market. These include globally recognized names like Agilent Technologies (NYSE: A), Illumina, Inc (NASDAQ: ILMN), Pacific Biosciences of California (NASDAQ: PACB), and Ludwig Enterprises (OTC: LUDG).

Ludwig is a relatively new name in the industry but it has already made quick work in establishing itself as a leader. By establishing the Ludwig mRNA Inflammation Index, Ludwig is creating a way to use genetic markets to detect cancer at an early stage and provide patient-specific treatments. Ludwig is focussing on determining the linkages between chronic inflammation and more serious diseases like cancer or even diabetes or heart disease.

Featured: $A $ILMN $PACB $LUDG

*Legal Disclaimer

Stay Connected
Latest News
From Sponsor
PubCo Insight. Deep Intelligence
Including AI Reports
for Savvy Investors

If you’re looking for a way to get an edge on the stock market, you need to check out PubCo Insight. Using AI, our system is able to make highly accurate stock picks that can help you achieve major gains. With our AI Reports, you’ll be able to learn which stocks are the most traded, undervalued, and have the most potential for growth. This valuable information is absolutely essential for anyone who wants to be successful in the stock market. So sign up now and get started on your path to success!

%d bloggers like this: